{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:56:45Z","timestamp":1756385805954},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"DOI":"10.7759\/cureus.29992","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T16:50:11Z","timestamp":1665075011000},"source":"Crossref","is-referenced-by-count":0,"title":["Neuroleptic Malignant Syndrome From Oxcarbazepine and Topiramate Withdrawal: An Unusual Case"],"prefix":"10.7759","author":[{"given":"Son","family":"Dang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachidanand","family":"Peteru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsen","family":"Askandaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700810","article-title":"Neuroleptic malignant syndrome\u2014an 11-year longitudinal case-control study","volume":"57","author":"Nielsen RE","year":"2012","unstructured":"Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome\u2014an 11-year longitudinal case-control study. Can J Psychiatry. 2012, 57:512-8. 10.1177\/070674371205700810","journal-title":"Can J Psychiatry"},{"key":"ref2","unstructured":"FDA adverse events reporting system. Qlik sense. (n.d.). (2021). Accessed. October 3, 2021: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/33a0f68e-845c-48e2-bc81-8141c6aaf772\/state\/a...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Ed). American Psychiatric Association, Washington, D.C; 2013. 10.1176\/appi.books.9780890425596https:\/\/doi.org\/10.1176\/appi.books.9780890425596."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson JL","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985, 142:1137-45. 10.1176\/ajp.142.10.1137","journal-title":"Am J Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145799001388","article-title":"Proposed research diagnostic criteria for neuroleptic malignant syndrome","volume":"2","author":"Mathews T","year":"1999","unstructured":"Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol. 1999, 2:129-44. 10.1017\/S1461145799001388","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.153.1.107","article-title":"Spectrum concept of neuroleptic malignant syndrome","volume":"153","author":"Adityanjee","year":"1988","unstructured":"Adityanjee, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry. 1988, 153:107-11. 10.1192\/bjp.153.1.107","journal-title":"Br J Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890420249.dsm-iv-tr","article-title":"","author":"American Psychiatric Association","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 2020 (ed): American Psychiatric Association, Washington, D.C; 10.1176\/appi.books.9780890420249.dsm-iv-tr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000640","article-title":"A validation study of the International Consensus Diagnostic Criteria for neuroleptic malignant syndrome","volume":"37","author":"Gurrera RJ","year":"2017","unstructured":"Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the International Consensus Diagnostic Criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2017, 37:67-71. 10.1097\/JCP.0000000000000640","journal-title":"J Clin Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06438","article-title":"An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method","volume":"72","author":"Gurrera RJ","year":"2011","unstructured":"Gurrera RJ, Caroff SN, Cohen A, et al.. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011, 72:1222-8. 10.4088\/JCP.10m06438","journal-title":"J Clin Psychiatry"},{"key":"ref10","article-title":"Pathophysiology and therapy of malignant neuroleptic syndrome [Article in German]","volume":"63","author":"Weller M","year":"1992","unstructured":"Weller M, Kornhuber J. Pathophysiology and therapy of malignant neuroleptic syndrome [Article in German]. Nervenarzt. 1992, 63:645-55.","journal-title":"Nervenarzt"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2016.59","article-title":"Neuroleptic malignant syndrome associated with lithium toxicity","volume":"31","author":"Patil V","year":"2016","unstructured":"Patil V, Gupta R, Verma R, Balhara YP. Neuroleptic malignant syndrome associated with lithium toxicity. Oman Med J. 2016, 31:309-11. 10.5001\/omj.2016.59","journal-title":"Oman Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2005.07.049","article-title":"Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine","volume":"390","author":"Clinckers R","year":"2005","unstructured":"Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett. 2005, 390:48-53. 10.1016\/j.neulet.2005.07.049","journal-title":"Neurosci Lett"},{"key":"ref13","article-title":"The protective action of topiramate on dopaminergic neurons","volume":"16","author":"Huang S","year":"2010","unstructured":"Huang S, Wang H, Xu Y, Zhao X, Teng J, Zhang Y. The protective action of topiramate on dopaminergic neurons. Med Sci Monit. 2010, 16:BR307-12.","journal-title":"Med Sci Monit"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S135666","article-title":"Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia","volume":"13","author":"Huang Y","year":"2017","unstructured":"Huang Y, Ma H, Wang Y, Peng M, Zhu G. Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia. Neuropsychiatr Dis Treat. 2017, 13:1395-7. 10.2147\/NDT.S135666","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033519","article-title":"Topiramate treatment is neuroprotective and reduces oligodendrocyte loss after cervical spinal cord injury","volume":"7","author":"Gensel JC","year":"2012","unstructured":"Gensel JC, Tovar CA, Bresnahan JC, Beattie MS. Topiramate treatment is neuroprotective and reduces oligodendrocyte loss after cervical spinal cord injury. PLoS One. 2012, 7:e33519. 10.1371\/journal.pone.0033519","journal-title":"PLoS One"},{"key":"ref16","article-title":"Oxcarbazepine","author":"Preuss CV","year":"2022","unstructured":"Preuss CV, Randhawa G, Wy TJP, Saadabadi A. Oxcarbazepine. StatPearls [Internet], Treasure Island (FL); 2022."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.128579","article-title":"Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome","volume":"17","author":"Chatterjee A","year":"2014","unstructured":"Chatterjee A. Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome. Ann Indian Acad Neurol. 2014, 17:123-4. 10.4103\/0972-2327.128579","journal-title":"Ann Indian Acad Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF02252624","article-title":"Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis","volume":"6","author":"Kornhuber J","year":"1993","unstructured":"Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect. 1993, 6:63-72. 10.1007\/BF02252624","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1614.1999.00630.x","article-title":"Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases","volume":"33","author":"Trollor JN","year":"1999","unstructured":"Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999, 33:650-9. 10.1080\/j.1440-1614.1999.00630.x","journal-title":"Aust N Z J Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn JR","year":"2007","unstructured":"Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007, 164:870-6. 10.1176\/ajp.2007.164.6.870","journal-title":"Am J Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199211000-00028","article-title":"Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome","volume":"31","author":"Woodbury MM","year":"1992","unstructured":"Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992, 31:1161-4. 10.1097\/00004583-199211000-00028","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13215","article-title":"The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome","volume":"142","author":"Kuhlwilm L","year":"2020","unstructured":"Kuhlwilm L, Sch\u00f6nfeldt-Lecuona C, Gahr M, Connemann BJ, Keller F, Sartorius A. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr Scand. 2020, 142:233-41. 10.1111\/acps.13215","journal-title":"Acta Psychiatr Scand"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852900013407","article-title":"Is lorazepam a treatment for neuroleptic malignant syndrome?","volume":"5","author":"Francis A","year":"2000","unstructured":"Francis A, Chandragiri S, Rizvi S, Koch M, Petrides G. Is lorazepam a treatment for neuroleptic malignant syndrome?. CNS Spectr. 2000, 5:54-7. 10.1017\/s1092852900013407","journal-title":"CNS Spectr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2018.7753","article-title":"Pulmonary embolism in a patient with neuroleptic malignant syndrome","volume":"10","author":"Almegren M","year":"2018","unstructured":"Almegren M. Pulmonary embolism in a patient with neuroleptic malignant syndrome. Hematol Rep. 2018, 10:7753. 10.4081\/hr.2018.7753","journal-title":"Hematol Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/258172","article-title":"Extensive deep venous thrombosis in a patient with neurolept malignant syndrome despite being on prophylaxis","volume":"2011","author":"Mathew JC","year":"2011","unstructured":"Mathew JC, Pillai U, Lacasse A. Extensive deep venous thrombosis in a patient with neurolept malignant syndrome despite being on prophylaxis. Case Rep Psychiatry. 2011, 2011:258172. 10.1155\/2011\/258172","journal-title":"Case Rep Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X17695999","article-title":"Neuroleptic malignant syndrome following catatonia: vigilance is the price of antipsychotic prescription","volume":"[Epub]","author":"Reilly TJ","year":"2017","unstructured":"Reilly TJ, Cross S, Taylor DM, Haslam R, Tomlin SC, Gaastra B. Neuroleptic malignant syndrome following catatonia: vigilance is the price of antipsychotic prescription. SAGE Open Med Case Rep. 2017, [Epub]:10.1177\/2050313X17695999","journal-title":"SAGE Open Med Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/114447-neuroleptic-malignant-syndrome-from-oxcarbazepine-and-topiramate-withdrawal-an-unusual-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:23Z","timestamp":1707508163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/114447-neuroleptic-malignant-syndrome-from-oxcarbazepine-and-topiramate-withdrawal-an-unusual-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.29992","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}